NCT00891436

Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms

Comparison of the Effect of Fluticasone Furoate Nasal Spray Versus Placebo on Allergic Mediators in the Tears of Subjects With Tree or Grass Pollen Allergy

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Rush University Medical Center · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

Rationale and objectives: Fluticasone furoate nasal spray (Veramyst) has been shown to improve ocular symptoms when used for the treatment of seasonal allergic rhinitis during the ragweed pollen season. Although this is the only published report of an intranasal corticosteroid shown to effectively treat ocular symptoms, the mechanism has not been delineated. Furthermore, the tears of patients with allergic conjunctivitis are known to have increased concentrations of cytokines and allergic mediators. The objective of this study is to determine if the positive effects of Veramyst nasal spray on ocular symptoms is via the inhibition of allergic mediators in the eyes. The investigators will conduct a double blind placebo controlled trial to determine if Veramyst nasal spray decreases the amount of allergic mediators in the tears of subjects randomized to Veramyst nasal spray versus placebo. The investigators will also compare the subjects' symptoms to the amount of allergic mediators detected in their tears.

Conditions

• Allergic Conjunctivitis to Tree Pollen or Grass Pollen

Interventions

Type	Name	Description
DRUG	Fluticasone furoate nasal spray	2 sprays each nostril every morning for 2 weeks
DRUG	Placebo nasal spray	2 sprays each nostril every morning for 2 weeks

Timeline

• Start date: 2009-04-01
• Primary completion: 2009-07-01
• Completion: 2009-08-01
• First posted: 2009-05-01
• Last updated: 2012-12-03
• Results posted: 2012-10-18

Locations

1 site across 1 country: United States